Assessing the utility of routine viral surveillance performed in children undergoing autologous stem cell transplantation at a single centre
Corresponding Author
David A. Foley
Department of Microbiology, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
School of Medicine, University of Western Australia, Perth, Western Australia, Australia
Correspondence
David A. Foley, PathWest Laboratory Medicine, QEII MC, PP Block, Hospital Ave, Nedlands, WA 6009, Australia.
Email: [email protected]
Search for more papers by this authorJessica Win See Wong
Department of General Paediatrics, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorAoife Keane
Department of General Paediatrics, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorShanti Ramachandran
Department of Oncology, Haematology and Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia
School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia
Search for more papers by this authorChristopher C. Blyth
Department of Microbiology, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
School of Medicine, University of Western Australia, Perth, Western Australia, Australia
Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorDaniel K. Yeoh
Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this authorCorresponding Author
David A. Foley
Department of Microbiology, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
School of Medicine, University of Western Australia, Perth, Western Australia, Australia
Correspondence
David A. Foley, PathWest Laboratory Medicine, QEII MC, PP Block, Hospital Ave, Nedlands, WA 6009, Australia.
Email: [email protected]
Search for more papers by this authorJessica Win See Wong
Department of General Paediatrics, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorAoife Keane
Department of General Paediatrics, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorShanti Ramachandran
Department of Oncology, Haematology and Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia
School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia
Search for more papers by this authorChristopher C. Blyth
Department of Microbiology, PathWest Laboratory Medicine, Nedlands, Western Australia, Australia
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
School of Medicine, University of Western Australia, Perth, Western Australia, Australia
Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia
Search for more papers by this authorDaniel K. Yeoh
Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this authorAbstract
We assessed the utility of routine viral surveillance for cytomegalovirus, Epstein–Barr virus and human adenovirus in children <16 years, undergoing autologous stem cell transplantation (ASCT) at a single centre over a 10-year period. A total of 85 ASCT were performed in 65 patients. Routine viral surveillance resulted in a high number of tests performed (median 20 tests per ASCT), without any clinically significant viral detections. These data support the limited clinical utility of routine viral surveillance in children undergoing ASCT. Adopting a clinically driven approach for viral testing is likely to be both cost-effective and safe.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.
REFERENCES
- 1Choi YB, Yi ES, Kang JM, et al. Infectious complications during tandem high-dose chemotherapy and autologous stem cell transplantation for children with high-risk or recurrent solid tumors. PLoS One. 2016; 11(9):e0162178. doi:10.1371/journal.pone.0162178
- 2Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther. 2005; 5(5): 835-846. doi:10.1586/14737140.5.5.835
- 3Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012; 14(6): 555-563. doi:10.1111/tid.12022
- 4Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein–Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803-811. doi:10.3324/haematol.2016.144428
- 5Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of Cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(8): e260-e272. doi:10.1016/S1473-3099(19)30107-0
- 6Kim JH, Goulston C, Sanders S, et al. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant. 2012; 18(11): 1753-1758. doi:10.1016/j.bbmt.2012.06.008
- 7Falcon CP, Broglie L, Phelan R, Choi SW, Auletta JJ, Chewning JH. Infection prophylaxis patterns following pediatric autologous hematopoietic stem cell transplantation: a survey of Pediatric Transplant and Cell Therapy Consortium centers. Pediatr Transplant. 2020; 24(8):e13821. doi:10.1111/petr.13821
- 8 Medicare Benefits Schedule (MBS) Online. Australian Government, Department of Health and Aged Care. Accessed February 1, 2022. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/downloads
- 9Inazawa N, Hori T, Nojima M, et al. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017; 89(2): 358-362. doi:10.1002/jmv.24621
- 10Srinivasan A, McLaughlin L, Wang C, et al. Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience. Transpl Infect Dis. 2014; 16(1): 90-97. doi:10.1111/tid.12165
- 11Mengarelli A, Annibali O, Pimpinelli F, et al. Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. J Infect. 2016; 72(2): 265-268. doi:10.1016/j.jinf.2015.11.005
- 12Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(5): 281-289. doi:10.1053/bbmt.2002.v8.pm12064366
- 13Frère P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006; 76(2): 102-108. doi:10.1111/j.1600-0609.2005.00569.x
